دورية أكاديمية

1143PD - Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)

التفاصيل البيبلوغرافية
العنوان: 1143PD - Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
المؤلفون: Konstantinopoulos, P.A., Sachdev, J.C., Schwartzberg, L., Matulonis, U.A., Sun, P., Wang, J.Y., Guo, W., Bobilev, D., Aktan, G., Karantza, V., Dezube, B., Vinayak, S.
المصدر: In Annals of Oncology September 2017 28 Supplement 5:v406-v407
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1093/annonc/mdx376.009